IBD is a key R&D focus for MSD, whose pipeline in the indication is currently led by tulisokibart, an anti-TL1A antibody in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results